Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
Top Page
Atea Pharmaceuticals
(NASDAQ:AVIR)
Select Model
Select Model
Rating:57Neutral
Price Target:
$6.00
▲(1.52% Upside)
Action:ReiteratedDate:03/07/26
The score is held back primarily by weak financial performance (no revenue since 2022, large ongoing losses, and sustained cash burn). Offsetting factors include strong technical momentum (despite overbought conditions) and a generally constructive earnings call focused on near-term Phase III milestones and a stated cash runway through 2027; valuation remains constrained by losses and lack of dividend support.
Positive Factors
Clinical efficacy (Phase II)
High Phase II cure rates and a demonstrated high barrier to resistance provide durable clinical differentiation versus incumbents. Strong efficacy reduces development risk for Phase III readouts and supports favorable uptake assumptions for payers and prescribers if replicated in pivotal trials.
Cash runway and low leverage
A multi-year cash runway and near-zero debt materially lower near-term financing risk, enabling completion of Phase III programs and prelaunch activities without immediate dilution. This financial flexibility supports execution on pivotal milestones over the 2–3 year horizon.
Commercial preparedness and prescriber interest
Proactive commercial planning, targeted field force sizing and independent prescriber research signal realistic go‑to‑market readiness. Early payer interest and prescriber intent reduce commercialization execution risk and support potential uptake if regulatory approvals are secured.
Negative Factors
Sustained negative cash flow
Persistent multi-year negative operating and free cash flow signals ongoing reliance on external financing or dilution to fund R&D. Over the medium term this elevates execution and funding risk, particularly if clinical timelines slip or fundraising windows tighten.
Shrinking equity and asset base
A materially smaller equity and asset base reflects accumulated losses and limits balance sheet firepower for M&A, manufacturing scale-up, or prolonged commercialization support. Reduced financial cushion increases vulnerability to adverse trial or market outcomes.
Post-launch royalty and milestone obligations
Contractual milestone and royalty obligations materially reduce the net economics of any approved product. Over the long term this lowers gross-to-net margins and cash returns from commercialization, affecting reinvestment capacity and shareholder economics.
Atea Pharmaceuticals (AVIR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$478.03M
Dividend YieldN/A
Average Volume (3M)575.96K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth14.33%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding79,672,080
10 Day Avg. Volume829,495
30 Day Avg. Volume575,960
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.26
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$7.10Price Target Upside20.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Atea Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyAtea Pharmaceuticals generates revenue through partnerships, collaborations, and potential future sales of its antiviral therapeutic products. The company has entered into significant partnerships, such as its collaboration with Roche, to fund development and commercialization of its product candidates. Revenue streams may include milestone payments, royalties, and licensing fees associated with these collaborations. Additionally, upon successful approval and commercialization of its drugs, Atea would earn revenue from direct sales of its antiviral therapies.
Atea Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
Overall the call conveyed substantial forward momentum: the HCV Phase III program is advancing to expected topline readouts this year, Phase II data show high efficacy (95% mITT, 98% per-protocol), a well-capitalized balance sheet ($301.8M) with runway through 2027, and a promising new HEV program (AT-587) moving into first-in-human studies. Notable risks include a growing HCV treatment gap, competitive/pricing pressures, regional regulatory endpoint differences, concentrated prescriber dynamics, and the early-stage nature of the HEV program; milestone and royalty obligations to Merck will affect post-launch economics. On balance, the positives—clinical progress, strong efficacy signals, commercial planning and financial resources—outweigh the risks communicated on the call.Q4-2025 Updates
Positive Updates
Phase III HCV program on track with imminent topline readouts
Completed enrollment for the North American trial C-BEYOND (company reported completion in December) and expect topline results for C-BEYOND midyear and for global C-FORWARD by year-end; combined program expected to enroll >1,760 patients across both trials; studies are randomized 1:1 versus standard of care and powered 90% with a 5% non-inferiority margin.
Strong Phase II efficacy supporting potential best-in-class profile
Phase II (n=275) 8-week bemnifosbuvir+ruzasvir regimen achieved 98% SVR12 in the per-protocol treatment-adherent population and 95% SVR12 in the efficacy-evaluable (mITT) population; regimen demonstrated high barrier to resistance and multi-mechanism antiviral activity.
Favorable safety/administration and drug-drug interaction profile
Regimen has low risk for drug-drug interactions (including proton pump inhibitors and standard HIV therapy), no food effect, and no dose adjustment required for hepatic or renal impairment—features that support convenience and potential suitability for the test-and-treat model.
Commercial preparation and prescriber interest
Company is preparing commercial launch (anticipated focused specialty sales force ~75 people), low cost of goods relative to net price, blister pack dosing for adherence, and independent market research (IQVIA, 153 high-prescribers) indicating physicians would likely prescribe the regimen to ~50% of their HCV patients; payers expressed interest in formulary inclusion.
Strong financial position and runway
Cash, cash equivalents and marketable securities of $301.8 million as of December 31, 2025; company expects cash runway to extend through 2027 and to prioritize spending on completing Phase III and prelaunch activities.
Strategic expansion into Hepatitis E (HEV) with lead AT-587
Selected AT-587 as lead HEV candidate after supporting in vitro and in vivo data showing potent nanomolar activity (genotype 3) and conversion to active triphosphate in human hepatocytes; plan to initiate first-in-human study midyear with proof-of-concept expected by year-end and potential Phase II/III in H2 2027; estimated HEV market opportunity $750M–$1B annually (orphan potential).
Scientific validation and visibility
Presented datasets at EASL 2025, AASLD Liver Meeting 2025, CROI 2026 and JPM 2026 reinforcing regimen profile and AT-587 preclinical data, including data demonstrating additional antiviral mechanisms (inhibition of HCV virion assembly/secretion).
Capital return and disciplined spending
Returned $25 million to shareholders via share repurchase in 2025 while increasing R&D spend to advance Phase III programs and reducing G&A through lower stock-based compensation; company emphasizes financial discipline while funding core programs.
Negative Updates
Growing HCV incidence and treatment gap
Reported ~160,000 new chronic HCV infections in the U.S. annually but only ~85,000 patients treated per year (only ~53% of newly reported infections treated), indicating a persistent treatment gap and public health challenge.
Public health targets missed and rising liver cancer incidence
Company highlighted that most countries, including the U.S., are not on track to meet WHO hepatitis C elimination goals by 2030 (estimates push beyond 2050) and projected liver cancer incidence to increase by >50% in the next 5 years (from ~850,000 cases in 2025 to ~1.4 million).
Competitive and pricing pressures in DAA market
Legacy regimens face pricing pressure (company noted Epclusa net pricing declined while Mavyret pricing rose slightly year-over-year); market share dynamics are competitive (market shares approaching 50/50 among key agents), which could challenge uptake and pricing elasticity.
Regulatory and endpoint complexity across regions
Different primary analysis preferences for regulators (U.S. FDA favors mITT; EMA favors per-protocol) mean the program uses two distinct primary endpoint analysis sets, which could complicate cross-jurisdiction interpretation and regulatory interactions.
Concentration risk among prescribers
Approximately 6,000 prescribers write 80% of DAA prescriptions in the U.S., creating dependency on a concentrated prescriber base for efficient commercialization and potential access barriers if key accounts are not converted.
Early-stage HEV program risk
AT-587 is supported by preclinical data but remains preclinical/early clinical—first-in-human planned midyear—so clinical efficacy, safety and regulatory approval timelines and probabilities remain uncertain.
Costs and future royalties reduce net economics
Company in-licensed ruzasvir from Merck and will pay milestone and royalty payments upon NDA submission/approval (next milestone tied to NDA and approval anticipated ~2027), which will impact net economics post-launch.
Inconsistent enrollment figures noted in the call
Transcript contains conflicting enrollment numbers for C-BEYOND (Jean-Pierre stated 'over 880 patients' while later management referenced 'more than 180 patients'), representing either a communication inconsistency in the call or a potential transcription/clarification issue that may need resolution.
Company Guidance
Atea’s guidance focused on 2026 as a pivotal year: top‑line Phase III readouts for C‑BEYOND are expected midyear and for C‑FORWARD by year‑end (both randomized 1:1 vs sofosbuvir/velpatasvir, primary endpoint SVR24), with the global program powered at 90% with a 5% non‑inferiority margin and expected ~95% mITT SVR (98% per‑protocol in Phase II); C‑BEYOND enrollment was completed in December (reported >880 patients) and C‑FORWARD enrollment is expected to finish midyear to bring the combined program to >1,760 patients across ~240 sites (~120 in North America and ~120 in 17 countries outside NA), with 8‑week BEM‑RZR dosing for non‑cirrhotics vs 12 weeks for standard of care (12 weeks for cirrhotics). Financially, Atea reported $301.8M in cash, cash equivalents and marketable securities as of 12/31/2025, a cash runway through 2027, and returned $25M in a 2025 share repurchase; commercial preparation includes a planned ~75‑person field force, targeting ~6,000 prescribers who write 80% of DAA scripts, and market research (IQVIA, 153 high prescribers) showing ~50% likely use. The company also guided expansion into HEV with AT‑587 (selected Jan 2026), IND/CTA‑enabling studies underway, first‑in‑human midyear 2026 with proof‑of‑concept by year‑end and potential Phase II/III in H2 2027, and an estimated HEV market opportunity of $750M–$1B.Atea Pharmaceuticals Financial Statement Overview
Summary
Financials reflect a prolonged development-stage burn profile: revenue has been $0 since 2022, net losses remain large (though slightly improved in 2025 vs. 2024), and operating/free cash flow is deeply negative with heavy cash burn. The main offset is very low leverage (minimal debt), but shrinking equity/assets and persistent losses elevate funding and execution risk.Income Statement
Operating performance has deteriorated sharply versus earlier years. Revenue fell from $351.4M (2021) to $0 in 2022–2025, and the company has remained deeply loss-making with net losses of $115.9M (2022), $136.0M (2023), $168.4M (2024), and $158.3M (2025). The key positive is that losses narrowed modestly in 2025 vs. 2024, but profitability is still materially negative and there is no revenue base in the most recent annual periods.18
Very Negative
Balance Sheet
The balance sheet shows very low financial leverage, with total debt of $0.8M in 2025 and a very low debt-to-equity ratio (~0.003). However, the equity base has been shrinking meaningfully (stockholders’ equity down from $710.1M in 2021 to $275.4M in 2025), reflecting sustained losses. Total assets also declined from $772.9M (2021) to $315.2M (2025), which reduces financial flexibility even though debt levels remain minimal.62
Positive
Cash Flow
Cash generation is weak and consistently negative in recent years, with operating cash flow of -$121.0M (2022), -$85.4M (2023), -$135.5M (2024), and -$132.0M (2025), resulting in similarly negative free cash flow. While 2023 showed a temporary improvement versus 2022, cash burn accelerated again in 2024 and remained heavy in 2025. The 2020 period showed unusually strong positive cash flow, but the more recent multi-year pattern indicates ongoing cash consumption.24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 351.37M |
| Gross Profit | -416.00K | -83.37M | -70.09M | -62.39M | 184.16M |
| EBITDA | -180.89M | -131.80M | -119.59M | -110.84M | 138.41M |
| Net Income | -158.35M | -168.38M | -135.96M | -115.91M | 121.19M |
Balance Sheet | |||||
| Total Assets | 315.22M | 464.67M | 594.97M | 666.71M | 772.89M |
| Cash, Cash Equivalents and Short-Term Investments | 301.83M | 454.72M | 578.11M | 646.71M | 764.38M |
| Total Debt | 843.00K | 1.64M | 2.40M | 3.12M | 197.00K |
| Total Liabilities | 39.78M | 25.80M | 39.78M | 26.14M | 62.81M |
| Stockholders Equity | 275.43M | 438.87M | 555.19M | 640.57M | 710.08M |
Cash Flow | |||||
| Free Cash Flow | -132.03M | -135.50M | -85.39M | -122.92M | -87.01M |
| Operating Cash Flow | -132.03M | -135.50M | -85.39M | -120.98M | -87.00M |
| Investing Cash Flow | 188.79M | 56.10M | 40.30M | -455.41M | -4.00K |
| Financing Cash Flow | -25.75M | 267.00K | 257.00K | 370.00K | 1.47M |
Atea Pharmaceuticals Technical Analysis
Positive
5.91
Price Trends
4.49
Positive
3.85
Positive
3.59
Positive
Market Momentum
0.50
Negative
70.81
Negative
74.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVIR, the sentiment is Positive. The current price of 5.91 is above the 20-day moving average (MA) of 5.35, above the 50-day MA of 4.49, and above the 200-day MA of 3.59, indicating a bullish trend. The MACD of 0.50 indicates Negative momentum. The RSI at 70.81 is Negative, neither overbought nor oversold. The STOCH value of 74.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVIR.
Atea Pharmaceuticals Risk Analysis
Atea Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Atea Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atea Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $478.03M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $266.40M | -3.25 | -22.37% | ― | 3.36% | 5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $151.75M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
48 Neutral | $154.09M | -10.73 | 304.91% | ― | 12.60% | 58.23% | |
46 Neutral | $167.52M | -5.01 | -99.45% | ― | -11.99% | -42.04% |
* Healthcare Sector Average
AVIR
Atea Pharmaceuticals
6.00
2.85
90.48%
CDXS
Codexis
1.67
-0.88
-34.51%
HRTX
Heron Therapeutics
0.82
-1.58
-65.96%
PRQR
ProQR
1.59
-0.04
-2.45%
TLSA
Tiziana Life Sciences
1.26
-0.03
-2.33%
OABI
OmniAb
1.84
-0.43
-18.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.